Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Progress in biophysics and molecular biology · 2021
    DPDoru Paul
    PMID: 33991584DOIFirst and senior author10 citations
  2. 2
    Progress in biophysics and molecular biology · 2021
    DPDoru Paul
    PMID: 34428429DOIFirst author4 citations
  3. 3
    American journal of nuclear medicine and molecular imaging · 2020
    DPDoru PaulEKEdward K FungSVShankar VallabhajosulaECElizabeta Cristina Popa
    PMID: 33329935PMCID: PMC7724279First author

Publications

28 publications

Clinical research

7 studies
Completed & closed trials (7)
  • PI
    Plasma Biomarkers for Weight and Muscle Loss in Pancreatic Cancer
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
  • PI
    Compassionate Use of APG 157 for Treatment of Esophagogastric Cancer in Patient F-C
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)
  • PI
    A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
    PHASE2 · National Cancer Institute · CLOSED TO ACCRUAL (as of 2025)
    Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    NCT05172258
  • PI
    Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
    PHASE1; PHASE2 · BeiGene USA · IRB STUDY CLOSURE (as of 2024)
    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in; HNSCC for Phase 2 Dose Expansion; NSCLC for Phase 2 Dose Expansion
    NCT03744468
  • PI
    A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
    PHASE3 · Merck Sharp & Dohme Corp · IRB STUDY CLOSURE (as of 2023)
    Head and Neck Neoplasms
    NCT03765918
  • PI
    A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
    PHASE3 · Merck Sharp & Dohme Corp · IRB STUDY CLOSURE (as of 2022)
    Head and Neck Squamous Cell Carcinoma
    NCT04199104
  • PI
    Phase 2 Study of OBP-301 (Telomelysin ™) in Combination With Pembrolizumab and Stereotactic Body Irradiation in Patients With Head and Neck Squamous Cell Carcinoma With Inoperable, Recurrent or Progressive Disease
    PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
    Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
    NCT04685499